Diagnostic Diagnostic Imaging Disease Radiopharmaceuticals 
AuntMinnie
MARCH 15, 2024
However, increased longevity has brought on a troubling rise in chronic disease, diminishing the quality of life later in life. Centers for Disease Control and Prevention (CDC) found that more than a quarter of U.S. An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care.
Imaging Technology
DECEMBER 6, 2023
and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Imaging Technology
JUNE 10, 2024
The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto. More recently, she and her collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, recently approved for human studies by the FDA as an Investigational New Drug.
Imaging Technology
MAY 30, 2023
milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,
Imaging Technology
JULY 28, 2023
POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Medical Officer of Blue Earth Diagnostics. Teoh, MBBS, MRCP, FRCR, D.Phil.,
Future Teleradiology
NOVEMBER 27, 2023
Teleradiology-India Introduction: Nuclear medicine continues to be at the forefront of cutting-edge technologies, pushing the boundaries of diagnostic and therapeutic capabilities. Revolutionary Radioisotopes: Expanding the Diagnostic Toolkit: Explore the latest developments in novel radioisotopes used in nuclear medicine.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
Expert insights. Personalized for you.
105 
Let's personalize your content